Secukinumab (Cosentyx)
Novartis
Description
Secukinumab is a fully human IgG1/k; monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment, secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions.
Indications
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Cosentyx alone or in combination with methotrexate (MTX) is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Also indicated for anklosing sponodylitis.
Price
2x 150mg solutions for injection in pre-filled syringe or pre-filled pen, £1218.78
More on: Systemic psoriasis treatments